BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 64,125 shares of the business’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $86.96, for a total value of $5,576,310.00. Following the completion of the sale, the chief executive officer now owns 378,184 shares of the company’s stock, valued at $32,886,880.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.65, for a total value of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.34, for a total value of $13,096,665.12.
  • On Tuesday, August 16th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.49, for a total value of $3,812,022.34.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 85.45 on Tuesday. BioMarin Pharmaceutical Inc. has a one year low of $62.12 and a one year high of $118.48. The firm has a 50-day moving average price of $94.32 and a 200-day moving average price of $89.71. The company’s market capitalization is $13.97 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($2.61) EPS for the quarter, missing the consensus estimate of ($0.52) by $2.09. The firm had revenue of $300.10 million for the quarter, compared to the consensus estimate of $278.75 million. BioMarin Pharmaceutical had a negative net margin of 54.53% and a negative return on equity of 11.99%. BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.51) earnings per share. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.95) earnings per share for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

A number of analysts have recently weighed in on the company. Robert W. Baird set a $115.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Saturday. Leerink Swann reiterated an “outperform” rating and set a $127.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, October 13th. Goldman Sachs Group Inc. upgraded BioMarin Pharmaceutical to a “neutral” rating in a research report on Friday, October 7th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $106.00 target price for the company in a research report on Tuesday, October 4th. Finally, Cowen and Company set a $150.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, September 8th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $118.31.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of BioMarin Pharmaceutical by 3.1% in the second quarter. Vanguard Group Inc. now owns 11,448,690 shares of the company’s stock valued at $890,708,000 after buying an additional 346,369 shares during the period. Jennison Associates LLC raised its position in shares of BioMarin Pharmaceutical by 3.4% in the second quarter. Jennison Associates LLC now owns 9,051,244 shares of the company’s stock valued at $704,187,000 after buying an additional 301,353 shares during the period. Primecap Management Co. CA raised its position in shares of BioMarin Pharmaceutical by 0.3% in the first quarter. Primecap Management Co. CA now owns 7,350,369 shares of the company’s stock valued at $606,258,000 after buying an additional 19,680 shares during the period. State Street Corp raised its position in shares of BioMarin Pharmaceutical by 1.9% in the second quarter. State Street Corp now owns 3,349,037 shares of the company’s stock valued at $260,556,000 after buying an additional 62,294 shares during the period. Finally, Palo Alto Investors LLC raised its position in shares of BioMarin Pharmaceutical by 29.6% in the second quarter. Palo Alto Investors LLC now owns 1,737,399 shares of the company’s stock valued at $135,170,000 after buying an additional 397,052 shares during the period. Hedge funds and other institutional investors own 93.08% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.